MX2020000295A - Compuestos de benzoxazol y benzofurano sustituidos como inhibidores de pde7. - Google Patents

Compuestos de benzoxazol y benzofurano sustituidos como inhibidores de pde7.

Info

Publication number
MX2020000295A
MX2020000295A MX2020000295A MX2020000295A MX2020000295A MX 2020000295 A MX2020000295 A MX 2020000295A MX 2020000295 A MX2020000295 A MX 2020000295A MX 2020000295 A MX2020000295 A MX 2020000295A MX 2020000295 A MX2020000295 A MX 2020000295A
Authority
MX
Mexico
Prior art keywords
substituted benzoxazole
pde7 inhibitors
benzofuran compounds
chemical entities
benzofuran
Prior art date
Application number
MX2020000295A
Other languages
English (en)
Inventor
Mi Chen
Vincent John Santora
Demichael Chung
Original Assignee
Dart Neuroscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dart Neuroscience Llc filed Critical Dart Neuroscience Llc
Publication of MX2020000295A publication Critical patent/MX2020000295A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Entidades químicas de benzoxazol y benzofurano sustituidos de la Fórmula (I): (ve Fórmula) en donde, V, W, X, Y, Z, y m tienen cualquiera de los valores descritos en la presente y composiciones que comprenden tales entidades químicas; procesos para elaborarlos; y su uso en una amplia gama de métodos, incluyendo estudios metabólicos y cinéticos de reacción; técnicas de detección y representación de imágenes; tratamientos radiactivos; y el tratamiento de uno o más trastornos, incluyendo trastornos neurológicos, cognitivos, inmunológicos e inflamatorios, así como otras afecciones y enfermedades que implican PDE7 o la señalización de nucleótidos cíclicos.
MX2020000295A 2017-07-12 2018-07-11 Compuestos de benzoxazol y benzofurano sustituidos como inhibidores de pde7. MX2020000295A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762531802P 2017-07-12 2017-07-12
PCT/US2018/041565 WO2019014305A1 (en) 2017-07-12 2018-07-11 SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS

Publications (1)

Publication Number Publication Date
MX2020000295A true MX2020000295A (es) 2020-07-22

Family

ID=63036485

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000295A MX2020000295A (es) 2017-07-12 2018-07-11 Compuestos de benzoxazol y benzofurano sustituidos como inhibidores de pde7.

Country Status (9)

Country Link
US (1) US11685745B2 (es)
EP (1) EP3652180B1 (es)
JP (1) JP7213863B2 (es)
KR (1) KR102640696B1 (es)
CN (1) CN111094293A (es)
AU (1) AU2018300091B2 (es)
CA (1) CA3069432A1 (es)
MX (1) MX2020000295A (es)
WO (1) WO2019014305A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112574202B (zh) * 2020-12-11 2021-11-09 台州学院 一种螺喹唑啉-2-酮类衍生物及其制备方法和应用
WO2024038090A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US7491742B2 (en) 1999-10-21 2009-02-17 Merck Patent Gmbh Imidazole derivatives as phosphodiesterase VII inhibitors
DE19953024A1 (de) 1999-11-04 2001-05-10 Merck Patent Gmbh Isoxazolderivate als Phosphodiesterase VII-Hemmer
DE19953025A1 (de) 1999-11-04 2001-05-10 Merck Patent Gmbh Pyrrolderivate als Phosphodiesterase VII-Hemmer
DE19953414A1 (de) 1999-11-06 2001-05-10 Merck Patent Gmbh Imidazopyridinderivate als Phospodiesterase VII-Hemmer
DE19954707A1 (de) 1999-11-13 2001-05-17 Merck Patent Gmbh Imidazolverbindungen als Phosphodiesterase VII-Hemmer
US20030138815A1 (en) 2000-04-28 2003-07-24 Franz-Werner Kluxen Splice variant of camp phosphodiesterase type7(pde7a3)
GB0015095D0 (en) 2000-06-20 2000-08-09 Celltech Chiroscience Ltd Chemical compounds
NZ523456A (en) 2000-07-11 2004-11-26 Albany Molecular Res Inc Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
EP2316531A1 (en) 2000-08-10 2011-05-04 Cold Spring Harbor Laboratory Augmented cognitive training
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
WO2002076953A1 (en) * 2001-03-21 2002-10-03 Warner-Lambert Company Llc New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US6815448B2 (en) 2001-05-07 2004-11-09 Wyeth Azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-HT1A antagonists
EP1400244A1 (en) 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
JP4810426B2 (ja) 2004-07-01 2011-11-09 第一三共株式会社 Ｐｄｅ７阻害作用を有するチエノピラゾール誘導体
CA2599662A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of pde7 inhibitors for the treatment of neuropathic pain
KR101009554B1 (ko) 2005-12-02 2011-01-18 화이자 리미티드 Ｐｄｅ７ 억제제로서 스피로시클릭 퀴나졸린 유도체
BRPI0811623A2 (pt) 2007-05-15 2014-11-11 Helicon Therapeutics Inc Métodos para identificar genes envolvidos na formação de memória usando pequeno rna interferente (sirna)
CA2687944A1 (en) 2007-05-24 2008-11-27 Pfizer Limited Spirocyclic quinazoline derivatives and their use as pde7 inhibitors

Also Published As

Publication number Publication date
KR102640696B1 (ko) 2024-02-27
EP3652180B1 (en) 2023-11-29
WO2019014305A1 (en) 2019-01-17
KR20200027994A (ko) 2020-03-13
EP3652180A1 (en) 2020-05-20
JP2020526546A (ja) 2020-08-31
JP7213863B2 (ja) 2023-01-27
CA3069432A1 (en) 2019-01-17
AU2018300091B2 (en) 2023-06-22
AU2018300091A1 (en) 2020-01-30
CN111094293A (zh) 2020-05-01
US20220267351A1 (en) 2022-08-25
US11685745B2 (en) 2023-06-27

Similar Documents

Publication Publication Date Title
MX2019014514A (es) Compuestos para tratar la enfermedad de huntington.
NZ711598A (en) Substituted naphthyridine and quinoline compounds as mao inhibitors
UA113156C2 (xx) Циклобутилзаміщені похідні піролопіридину й піролопіримідину як інгібітори jak
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
PH12014502396B1 (en) Nitrogenated heterocyclic compound
MX2015016085A (es) Derivados de heterociclicos.
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
EA023631B9 (ru) Замещенные 5-фтор-1h-пиразолопиридины и их применение
EA201691461A1 (ru) Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
EA201201677A1 (ru) Производные гетероарилимидазолона в качестве ингибиторов jak
MX2020006290A (es) Dinucleotidos ciclicos como agonistas de sting.
WO2016061509A8 (en) Compositions and methods of treating muscular dystrophy
BR112015022474A8 (pt) compostos de piridina e pirazina substituídos como inibidores de pde4.
TR201818825T4 (tr) Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar
MX2018013164A (es) Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
EA201790207A8 (ru) Новые замещенные пиримидиновые соединения
PH12016502130A1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
MX2016001855A (es) Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio.
EA201490438A1 (ru) Антибактериальные 3,4-дигидро-1н-[1,8]нафтиридиноны, замещенные циклопента[c]пирролом
MX2015015162A (es) Agente de reduccion de acido urico.
MA38884A1 (fr) Composé de triazolopyridine, compositions et procédés d'utilisation associés
MX2020000295A (es) Compuestos de benzoxazol y benzofurano sustituidos como inhibidores de pde7.
MX2015000163A (es) Nuevos indazoles para el tratamiento y la profilaxis de la infeccion por virus sincitial respiratorio.